Intensive Care Medicine

, Volume 21, Supplement 2, pp S258–S263 | Cite as

Time course of cytokine levels in sepsis

  • L. G. Thijs
  • C. E. Hack
Original

Abstract

In severe sepsis, a network of proinflammatory cytokines (TNF, IL-lß, IL-6, IL-8) is activated and blood levels of these cytokines are elevated, albeit inconsistently and with large individual variations. In addition, elevated blood levels of anti-inflammatory cytokines (IL-10), as well as of soluble cytokine receptors (sTNF-RI and II, IL-lra), have been found. They seem to have a regulatory function in the host response. Levels of TNF and IL-6 are usually highest at the time of admission, whereas the time course of IL-lß levels (when detectable) can vary considerably. Limited data on IL-8 levels suggest that they may remain elevated for longer periods. Elevated levels of sTNFR and IL-lra may also persist for a prolonged period of time. The pathogenetic significance of these observations is still unclear, but persistingly high levels of proinflammatory cytokines may be associated with organ failure and mortality.

Key words

Cytokines Sepsis Mediators 

References

  1. 1.
    Waage A, Halstensen A, Espevik T (1987) Association between tumour necrosis factor in serum and fatal out-come in patients with meningococcal disease. Lancet I:355–357Google Scholar
  2. 2.
    Girardin E, Grau GE, Dayer JM, Roux-Lombard P, the J 5 Study Group, Lambert PH (1988) Tumor necrosis factor and interleukin 1 in the serum of children with severe infectious purpura. N Engl J Med 319:397–400Google Scholar
  3. 3.
    de Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. JAMA 262: 249–251Google Scholar
  4. 4.
    Debets JMH, Kampmeijer R, van der Linden MPMH, Buurman WA, van der Linden CJ (1989) Plasma tumor necrosis factor and mortality in critically ill patients. Crit Care Med 17:489–494Google Scholar
  5. 5.
    Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P (1989) Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 17:975–978Google Scholar
  6. 6.
    Calandra T, Baumgartner JD, Grau GE et al (1990) Prognostic values of tumor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J Infect Dis 161:982–987Google Scholar
  7. 7.
    Cannon JG, Tompkins RG, Gelfand JA et al (1990) Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79–84Google Scholar
  8. 8.
    Marks JD, Marks CB, Luce JM et al (1990) Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 141:94–97Google Scholar
  9. 9.
    Munoz C, Misset B, Fitting C, Blériot JP, Carlet J, Cavaillon JM (1991) Dissociation between plasma and monocyte-associated cytokines during sepsis. Eur J Immunol 21:2177–2184Google Scholar
  10. 10.
    Philippé J, Dooijewaard G, Offner F, Turion P, Baele G, Leoux-Roels G (1992) Granulocyte elastase, tumor necrosis factor-α and urokinase levels as prognostic markers in severe infection. Thromb Haemostas 68:19–23Google Scholar
  11. 11.
    Wortel CH, von der Möhlen MAM, van Deventer SJH et al (1992) Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels. J Infect Dis 166: 1367–1374Google Scholar
  12. 12.
    Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 103: 565–575Google Scholar
  13. 13.
    Casey LC, Balk RA, Bone RC (1993) Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 119:771–778Google Scholar
  14. 14.
    Van der Poll T, Jansen J, van Leenen D et al (1993) Release of soluble receptor for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 168:955–960Google Scholar
  15. 15.
    Martin C, Saux P, Mege J-L, Perrin G, Papazian L, Gouin F (1994) Prognostic values of serum cytokines in septic shock. Intensive Care Med 20:272–277Google Scholar
  16. 16.
    Girardin E, Roux-Lombard P, Grau GE et al (1992) Imbalance between tumor necrosis factor-alpha and soluble TNF receptor concentrations in severe meningococcaemia. Immunology 76:20–23Google Scholar
  17. 17.
    Rogy MA, Coyle SM, Oldenburg HSA et al (1994) Persistently elevated soluble tumor necrosis factor receptor and interleukin-1 receptor antagonist levels in critically ill patients. J Am Coll Surg 178:132–138Google Scholar
  18. 18.
    Damas P, Ledoux D, Nys M et al (1992) Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 215:356–362Google Scholar
  19. 19.
    Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T (1989) The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin-6, interleukin-1, and fatal outcome. J Exp Med 169:333–338Google Scholar
  20. 20.
    Fischer E, Van Zee KJ, Marano MA et al (1992) Interleukin-1 receptor antagonist circulates in experimental inflammation and in human disease. Blood 79:2196–2200Google Scholar
  21. 21.
    Helfgott DC, Tatter SB, Santhanam U et al (1989) Multiple forms of β2/IL-6 in serum and body fluids during acute bacterial infection. J Immunol 142:948–953Google Scholar
  22. 22.
    Hack CE, De Groot ER, Felt-Bersma RJF et al (1989) Increased plasma levels of interleukin-6 in sepsis. Blood 74: 1704–1710Google Scholar
  23. 23.
    Calandra T, Gerain J, Heumann D, Baumgartner J-D, Glauser MP, the Swiss-Dutch J5 Immunoglobulin Study Group (1991) High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 91:23–29Google Scholar
  24. 24.
    Frieling JTM, van Deuren M, Wijdenes J, Van der Linden CJ, Sauerwein RW (1994) Soluble interleukin-6 (IL-6) receptor levels in septic patients and relation with circulating IL-6. Intensive Care Med 20 [Suppl 1]:S64Google Scholar
  25. 25.
    Friedland JS, Suputtamongkol Y, Remick DG et al (1992) Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun 60:2402–2408Google Scholar
  26. 26.
    Hack CE, Hart M, Strack van Schijndel RJM et al (1992) Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 60:2835–2842Google Scholar
  27. 27.
    Halstensen A, Ceska M, Brandtzaeg P, Redl H, Naess A, Waage A (1993) Interleukin-8 in serum and cerbrospinal fluid from patients with meningococcal disease. J Infect Dis 167:471–475Google Scholar
  28. 28.
    Chollet-Martin S, Montravers P, Gibert C (1993) High levels of interleukin-8 in the blood and alveolar spaces of patients with pneumonia and adult respiratory distress syndrome. Infect Immun 61:4553–4559Google Scholar
  29. 29.
    Marchant A, Devière J, Byl B, De Groote D, Vincent J-L, Goldman M (1994) Interleukin-10 production during septicaemia. Lancet 343:707–708Google Scholar
  30. 30.
    Bean AGD, Fierberg RA, Andrade S, Menon S, Zlotnik A (1993) Interleukin-10 protects mice against staphylococcal enterotoxin B-induced lethal shock. Infect Immun 61:4937–4939Google Scholar
  31. 31.
    Howard M, Muchamuel T, Andrade S, Menon S (1993) Interleukin-10 protects mice form lethal endotoxemia. J Exp Med 177:1205–1208Google Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • L. G. Thijs
    • 1
  • C. E. Hack
    • 2
  1. 1.Medical Intensive Care Unit and Institute for Cardiovascular Research (ICaR-VU)Free University HospitalAmsterdamThe Netherlands
  2. 2.Central Laboratory of the Netherlands Red Cross Blood Transfusion ServiceAmsterdamThe Netherlands

Personalised recommendations